Clinical Trial Update: Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study evaluating carfilzomib with and without romidepsin in cutaneous T-cell lymphoma (CTCL) was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Carfilzomib (carfilzomib)
• Romidepsin (romidepsin)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 | Status: TERMINATED | Results posted: 2019-08-29